期刊
IMMUNOTHERAPY
卷 14, 期 3, 页码 185-193出版社
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2021-0269
关键词
COVID-19; cytokine release syndrome; EGFR; monoclonal antibody; nimotuzumab; SARS-CoV-2
类别
资金
- Cuban Ministry of Health
- Center of Molecular Immunology
Nimotuzumab, a safe anti-EGFR antibody, when used to treat patients with COVID-19, significantly improved clinical symptoms, reduced lung lesions, and prevented fibrosis.
Background: In COVID-19, EGFR production is upregulated in the alveolar epithelial cells. EGFR overexpression further activates STAT-3 and increases lung pathology. The EGFR pathway is also one of the major nodes in pulmonary fibrosis. Methods: Nimotuzumab, a humanized anti-EGFR antibody, was used to treat three patients with severe or moderate COVID-19. The antibody was administered in combination with other drugs included in the national COVID-19 protocol. Results: Nimotuzumab was well tolerated. IL-6 decreased from the first antibody infusion. Clinical symptoms significantly improved after nimotuzumab administration, and the CT scans at discharge showed major resolution of the lung lesions and no signs of fibrosis. Conclusion: Safe anti-EGFR antibodies like nimotuzumab may modulate COVID-19-associated hyperinflammation and prevent fibrosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据